Griffin Hospital wants Novo Nordisk to pay all expenses it has incurred due to the usage of the pens.
“Novo Nordisk knew or should have known, many years prior to the FDA regulation being issued, that its multi-dose insulin pens, and in particular those pens in use in health care institutions like Griffin Hospital, should have had labeling affixed directly to the pen indicating that it was for ‘single patient use only,'” the suit said.
Novo Nordisk did not immediately respond to a request for comment Tuesday.
Griffin Hospital is represented by David J. Robertson of Heidell Pittoni Murphy & Bach LLP.
Counsel information for Novo Nordisk was not immediately available Tuesday.
The case is Griffin Health Services Corporation, d/b/a Griffin et al. v. Novo Nordisk, Inc. et al., case number AAN-CV24-6056394-S, in the Superior Court in the Judicial District of Ansonia-Milford.
